FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists
FIB-4 is a strong prognostic tool to screen patients and refer them to specialists, in cACLD patients and pharmacologically treated type 2 diabetes, irrespective of treatment.
Authors
- Susana Rodrigues (ORCID: https://orcid.org/0000-0002-3261-2795)
- Annalisa Berzigotti (ORCID: https://orcid.org/0000-0003-4562-9016)
- Jaime Bosch
- Yuly P. Mendoza (ORCID: https://orcid.org/0000-0003-4595-4724)
- Naomi F. Lange (ORCID: https://orcid.org/0000-0002-9519-4949)
- Wiebke van Beurden
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
Publication Details
- Journal
- Journal of Diabetes and its Complications
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.jdiacomp.2025.108978
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00